Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy
Daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a Phase I/II clinical trial.
Read original article on Medical Xpress - latest medical and health news stories →